In fact, CD133-positive glioblastoma cells were associated with an invasive phenotype [37], and high CD133 expression is associated with in vitro resistance to chemotherapy involving activation of the AKT pathway in neuroblastoma cell model [38]. The gene discussed is PROM1; the disease is glioblastoma.